Using cloned DNA probes specific for two isoforms of cardiac myosin light chains (MLCs), nonphosphorylatable MLC, and phosphorylatable, regulatory MLC 2 , we have observed that the MLCi messenger RNA of ventricular type does not appear in detectable amounts in atrial cells of either normotensive Wistar-Kyoto rat strain (WKY) or spontaneously hypertensive rat strain (SHR). The messenger RNA of regulatory isoform of ventricular MLC2, on the other hand, is found in threefold excess in atria of SHR relative to that of age-matched WKY. The increased level of MLC2 messenger RNA is present even in 6-week-old SHR atria where there is no established overloading of the heart.
T he myosin polypeptides are the principal structural components of muscle fiber and play a major role in muscle contraction. Myosins, which consist of two heavy chains (MHC) and two pairs of light chains (MLC), are present in multiple isoforms. The composition of myosins varies markedly depending on the stage of development and differentiation and in response to changes in physiological and hormonal states of the cell. In many vertebrates, normal development, aging, and changes in thyroid state influence the cardiac myosin isozymic pattern. 1 The changes are also observed in experimental animal models of chronic work overloads, 2 hypophysectomy, 3 hypertension, 4 and diabetic heart. 3 In rats, a transition in composition of ventricular MHC isoform, V,->V 3 , occurs after chronic overloading of the heart. 6 It was later demonstrated that the changes in MHC isozymes can be entirely accounted for by changes in the levels of respective messenger RNA (mRNA), suggesting that the levels of MHC polypeptides, at least in part, are controlled by differential expression of the respective mRNAs. Cardiac myosins are particularly interesting for investigations of mechanisms underlying the changes in these polypeptides and of their physiological significance, because the expression of cardiac myosin genes switches in response to many specific stimuli that affect the cardiovascular s y s t e m . " Associated with the head region of MHC, where the ATPase activity is located, are four MLC polypeptides. In most vertebrates, the cardiac MLCs consist of one pair of nonphosphorylatable alkali MLC, (M,^27,000) and one pair of regulatory, phosphorylatable MLC 2 (M^19,000). The existence of a phos-phorylating enzyme for MLC 2 suggests a physiological role for M L Q polypeptide. The possible involvement of M L Q in regulation of the ATPase activity has been discussed. "~1 4 Other studies have suggested that MLCs play a role in interaction of myosin head region with actin. 13 " 18 It is, nevertheless, clear that distinct isoforms of MLC are present in different muscle types, suggesting that they are associated with different contractile properties of the muscle. Hypertrophy induced by chronic overloads results in impairment of performance of the heart with a simultaneous decrease in myosin ATPase activity. 19 -20 Thus, there appears to be a relation between myosin ATPase activity and pathogenesis of cardiac muscle diseases. 20 ' 21 The composition of human atrial and ventricular MLCs has been shown to change in response to increased pressure loads and subsequent hypertrophy. 2223 Likewise, the rate of incorporation of [H]leucine into the phosphorylated form of MLC 2 was reported to increase significantly in hypertrophic rat hearts as compared with sham-operated animals.
To understand the molecular mechanisms involved in cardiac hypertrophy, the spontaneously hypertensive rat strain (SHR) was used as a model system. In SHR there is a gradual increase in cardiac mass as a function of age-related increase in blood pressure, resulting in a natural progression of hypertrophy. 23 Using cardiac MLC 2 -specific complementary DNA (cDNA) cloned in our laboratory, we have recently shown that in 18-week-old SHR, when hypertrophy is well established, there is an increase in MLC 2 mRNA levels. 26 -27 In the following report, we have further extended these studies using cDNA probes specific for both MLC, and MLC 2 isoforms and monitored the levels of the respective mRNA in ventricular and atrial rat heart cells by the sensitive nuclease S, protection assay. We have observed that while no MLC, mRNA of ventricular type is detectable in the normotensive Wistar-Kyoto rat strain (WKY) and SHR atrial muscles, there is a selective increase in ventricular MLC 2 mRNA in both 6-week-old (nonhypertrophic) and 18-week-old (hypertrophic) SHR heart atria relative to that in WKY atria. Thus, it appears that even in the absence of established overloading of the heart in 6-week-old SHR, there is an apparently predetermined adaptive response that results in an increased expression of cardiac MLC 2 gene.
Materials and Methods
Male SHR and age-matched WKY were obtained from Charles River Laboratories, Wilmington, Massachusetts. Blood pressure measurements were performed in a parallel experiment on both strains of rats in Dr. L. Klaven's laboratory, Hoffmann-La Roche, Nutley, New Jersey. The rats were killed at 5-6 and 18-20 weeks of age, and heart tissues were excised and either stored frozen at -120° C or used immediately. At 5-6 weeks of age, there was no difference in blood pressure between WKY and SHR, as expected. However, a gradual increase, which was maximum at 18-20 weeks of age, was observed in SHR." Fresh or frozen ventricular and atrial tissues from 20 rats were combined separately, and RNA was extracted by homogenization in 4 M guanidinium thiocyanate as described previously. The homogenate was layered on 5.7 M CsCl solution and centrifuged at 100,000g for 20 hours. The RNA pellet was dissolved in Proteinase K buffer (0.1 M Tris, pH 7.5, 50 mM NaCl, 10 mM EDTA, 1% sodium dodecyl sulfate, and 100 g/ml Proteinase K), incubated at 37° C for 30 minutes, and then extracted twice with an equal volume of phenol: chloroform : isoamyl-alcohol and once with chloroform. The RNA was subsequently recovered by ethanol precipitation.
Uniformly labeled, single-stranded DNA probes for MLC, and MLC 2 were synthesized for nuclease S, protection assay. The DNA insert of plasmid pRLC267 was first subcloned into M13mpl8 phage vector. 28 The replicative form phage DNA was isolated and digested with Pvu II to determine the orientation of the insert in the recombinant phage. The single-stranded DNA probe for MLC 2 from plasmid pRLC429 was made as described previously. 27 For S, mapping, DNA probes were uniformly labeled using Ml3 universal primer. For hybridization, 100,000 counts/min of the probes were incubated with 10 /xg total RNA at 45° C for 6 hours in 10 ptl hybridization buffer containing 80% formamide, 400 mM NaCl, 40 mM PIPES, pH 6.5, and 10 mM EDTA. The mixture was then digested with nuclease S, (1,000 units, Bethesda Research Laboratories, Gaithersburg, Maryland) for 60 minutes at 37° C, and the hybrids, recovered by phenol extraction and ethanol precipitation, were examined on denaturing polyacrylamide gel by exposure to x-ray films. For quantitation of the hybridization signals, underexposed films were traced by a densitometer.
Results
Previous studies have shown that distinct MLC isotypes are present in both human and mouse atrial and ventricular muscle cells. 10 i 22 f 29 However, variations, such as the appearance of skeletal embryonic MLC, in fetal rat ventricles 10 and the presence of ventriculartype MLC 2 in human left atrium, 22 have been reported. We have used two cDNA probes, pRLC429 and pRLC267, specific for rat ventricular MLC 2 and MLC,, respectively, to examine the presence of the respective mRNA in atrial and ventricular tissues of both SHR and WKY. The plasmid pRLC429 was previously isolated in our laboratory by screening a cDNA library constructed from the rat ventricular mRNA. 27 For isolation of MLC, cDNA clone, a DNA probe of 63 nucleotides, representing the coding sequence corresponding to the C-terminal portion (169-189 amino acid residues) of the rat skeletal MLC,, 31 was chemically synthesized. This segment of sequence is also conserved in human cardiac MLC, isoform. 32 By screening the rat ventricular cDNA library with this DNA, we isolated a transformant whose DNA sequence showed strong homology to the two known amino acid sequences of chicken and human cardiac MLC, (C. Saidapet, C. Kumar, M. Periasamy, C. Mendola, M.A.Q. Siddiqui, unpublished observations). A detailed characterization of plasmid pRLC267 and the genomic clones from MLC, recently isolated in our laboratory will be published. Figure 1 shows the hybridization pattern of total RNA isolated from the ventricular and atrial tissues of 18-20- week-old normotensive Wistar-Kyoto rat strain (WKY) or agematched spontaneously hypertensive rat strain (SHR), was fractionated on 1.5% agarose-formaldehyde gel, transferred to nitrocellulose paper, and hybridized with nick-translated plasmid DNA probes as described previously. 34 WKY and SHR with MLC 2 and MLC, cDNA probes. Upon hybridization of size-fractionated total RNA on formaldehyde gel, RNA bands with strong hybridization signals at positions expected of MLC 2 and MLC, mRNA appeared. The background hybridization was possibly due to aggregation of RNA because it varied with RNA preparations and became weaker upon extensive prior denaturation of the RNA samples. The MLC, cDNA probe hybridized efficiently with ventricular RNA but not with RNA from the atrial tissues (Figure lb) , demonstrating the tissue specificity of the sequence. On the other hand, the probe for MLC 2 pRLC429 hybridized to both ventricular and atrial RNAs, although somewhat weakly to the latter (Figure la) .
In an attempt to reexamine the increase in MLC 2 mRNA and to ascertain whether the hybridizable MLC 2 mRNA sequence was identical to that of the probe, we used a sensitive nuclease S, protection assay. For this purpose, single-stranded DNA were uniformly labeled using phage M13mpl8 containing rat cardiac MLC 2 -and MLC r specific cDNA inserts as described earlier. 27 The RNA from both ventricles and atrial tissues of 6-week-old (nonhypertrophic) and 19week-old (hypertrophic) SHR hearts were compared with RNA from the age-matched normotensive WKY hearts. In 6-week-old SHR, the blood pressure is similar to that of normal rat. 23 A gradual increase in blood pressure is observed soon after 6-7 weeks of age, and by 18-20 weeks, the hypertrophy is well established. As shown in Figure 2 , using MLC 2 -specific, singlestranded DNA probe, the entire coding segment of 446 bases present in the probe was protected against nuclease S,, indicating that the RNA sequences in normal and hypertensive rats are identical in both atrial and ventricular tissues. There was some increase (-25%) in the intensity of protected label in 19-week-old SHR ventricular RNA relative to WKY, which is consistent with the overall increase in MHC isozymes reported earlier in experimentally induced hypertrophic rat heart muscles, 2 but the RNA from atrial tissues of 19week-old SHR showed a threefold increase compared with the age-matched WKY. Such an increase was also found in the 6-week-old SHR atria. No protection was observed with transfer RNA used as control. It is noteworthy that in 19-week-old WKY hearts, there is an increase in the ventricular MLC 2 mRNA level in the atrial tissues relative to the 6-week-old animals. This might be the result of the normal growth and hypertrophy in cardiocytes, but the SHR atria contain much higher levels of ventricular MLC 2 mRNA compared with the age-matched WKY atria.
Thus, it appears that in genetically induced hypertensive and subsequent hypertrophic conditions, the level of MLC 2 mRNA of ventricular type increases preferentially in the atrial cells. In contrast, it is found by using S, protection assay with plasmid pRLC267 that the ventricular MLC, cDNA is not present in the atrial tissues of either SHR or WKY (Figure 3, lanes 5 -8) , suggesting that the MLC, isoform in atrial cells is different from that of ventricular MLC|. The multiple bands in protected DNA (Figure 3, lanes 1-4) are due to nuclease S,-sensitive breathing, which is usually observed with short DNA fragments.
Discussion
Our recent results 26 -27 suggest that the previously reported 24 increase in MLC 2 in hypertrophic heart is due to an increase in accumulation of MLC 2 mRNA. These results are also in agreement with the changes observed in composition of MLCs in human heart in response to pressure overloads and subsequent hypertrophy. 23 An increase also occurs in mRNA for cardiac a-actin in adult rat heart after aortic stenosis. 32 Distinct MLC 2 isotypes have previously been reported in human right and left atria. 22 Although MLC in the human adult right atria appears to contain essentially only atrial MLC, and MLC 2 , the left atria contains a ventricular-type MLC 2 . Moreover, variations in the amount of ventricular MLC 2 in the left atrium are found in different human specimens. In patients with a significant amount of ventricular MLC 2 isoform expressing in the left atrium, the stenosis of the mitral valve causes markedly elevated left atrial pressures and subsequent atrial hypertrophy. There is an apparent transition in terms of MLC 2 composition, from atrial to ventricular type, in response to increased pressure load and subsequent hypertrophy in human hearts. 23 Such a transition has also been observed in developing human heart. 22 bo 1 2 3 4 5 6 7 8 FIGURE 3 . Nuclease St protection analysis of various RNA with single-stranded pRLC267 DNA cloned into phage M13mpl8 vector. A uniformly labeled DNA corresponding to plasmid pRLC267 was prepared as described in Figure 2 and "Materials and Methods." Lanes 1 -4, protection with ventricle RNA; lanes5-8, protection with atrialRNA. Lanes 1 and5, 19- week-old normotensive Wistar-Kyoto rat strain (WKY); lanes 2 and 6, 19-week-old spontaneously hypertensive rat strain (SHR) ; lanes 3 and 7, 16-week-old WKY; lanes 4 and 8, 16 week-old SHR. Major slow-moving band in lanes 1 -4 protected against nuclease 5/ is 118 bp in length corresponding to total coding segment in pRLC267.
The changes in the expression of these contractile proteins are probably in response to new functional requirements of the heart, which raises interesting questions regarding mechanisms underlying control of expression of these genes and its relevance to muscle physiology. We have shown that in SHR there is a selective increase in ventricular type MLC 2 mRNA, which is predominantly localized in atrial cells. More significant, the increase can be detected in 6-week-old SHR prior to the onset of hypertrophy, suggesting that the high-level expression of ventricular MLC 2 gene in SHR atria is a predetermined event and is not due to the normal growth in cardiocytes. These observations correlate well with other findings on ventricular MLC 2level increases in hypertrophic rat and suggest that the changes occur at the mRNA level.
The Northern blot analysis and the nuclease S, protection experiments indicate that the MLC, isoform is not expressed in the atrial tissues in both WKY and SHR. Apparently, the MLC, sequences of rat atria are different from that of ventricle. Distinct ventricularand atrial-type MLC, isoforms have been reported in mice. 29 However, the ventricular MLC, also appears in slow skeletal muscle. Likewise, atrial MLC, A is also found in fetal skeletal muscle, 33 and skeletal muscle embryonic MLC, isoform is present in fetal rat ventricles. 10 In contrast to skeletal and ventricular muscles, the atria apparently retain MLC that is essentially fetal or embryonic in nature during early adult life.
The slow appearance of ventricular type MLC 2 in 19-week-old WKY may denote a progressive change in atrial myofibrillar composition from embryonic to adult state that is augmented in young SHR, presumably in response to some genetic stimuli associated with the spontaneously hypertensive character, and in the subsequently hypertrophied heart. Whatever the time course of the appearance of MLC 2 and the nature of stimuli may be, the physiological consequences of changes in MLC 2 gene expression in atria may play an important role in the functional adaptation of the myocardium that offers a unique opportunity for elucidation of the underlying mechanisms. 3435 
